Clinical Outcome of Beta-Tricalcium Phosphate Use for Bone Defects after Operative Treatment of Benign Tumors
Clinics in Orthopedic Surgery
; : 233-236, 2019.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-739482
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
We investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors.METHODS:
Between March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months.RESULTS:
When the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found (p = 0.184).CONCLUSIONS:
Purified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Prospective Studies
/
Bone Transplantation
/
Bone Remodeling
/
Transplants
/
Allografts
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Clinics in Orthopedic Surgery
Year:
2019
Document type:
Article